Replimune Group (NASDAQ:REPL) Trading Down 5.4% – Should You Sell?

Replimune Group, Inc. (NASDAQ:REPL) traded down 5.4% during mid-day trading on Thursday . The stock traded as low as $7.36 and last traded at $7.2950. 522,393 shares traded hands during trading, a decline of 50% from the average session volume of 1,043,914 shares. The stock had previously closed at $7.71.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on REPL shares. Leerink Partners raised Replimune Group from a “market perform” rating to an “outperform” rating and upped their price objective for the stock from $3.00 to $13.00 in a report on Monday, October 20th. JPMorgan Chase & Co. upgraded shares of Replimune Group from an “underweight” rating to a “neutral” rating and set a $11.00 price objective for the company in a report on Monday, October 20th. Wedbush raised shares of Replimune Group from a “neutral” rating to an “outperform” rating and upped their target price for the stock from $4.00 to $18.00 in a research note on Monday, October 20th. HC Wainwright raised shares of Replimune Group from a “neutral” rating to a “buy” rating and set a $12.00 target price for the company in a research report on Monday, October 27th. Finally, Leerink Partnrs upgraded Replimune Group from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 20th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, Replimune Group presently has a consensus rating of “Moderate Buy” and a consensus price target of $9.75.

Replimune Group Price Performance

The company has a current ratio of 6.31, a quick ratio of 6.31 and a debt-to-equity ratio of 0.26. The firm has a market cap of $558.04 million, a price-to-earnings ratio of -2.05 and a beta of 0.72. The company’s 50-day moving average is $9.40 and its 200-day moving average is $7.56.

Replimune Group (NASDAQ:REPL) last released its earnings results on Thursday, November 6th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.03). Equities research analysts predict that Replimune Group, Inc. will post -2.97 earnings per share for the current year.

Insider Buying and Selling at Replimune Group

In other news, insider Christopher Sarchi sold 5,208 shares of the firm’s stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $9.10, for a total transaction of $47,392.80. Following the completion of the transaction, the insider directly owned 123,088 shares in the company, valued at $1,120,100.80. This trade represents a 4.06% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Kapil Dhingra sold 3,169 shares of the company’s stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $10.40, for a total value of $32,957.60. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 25,625 shares of company stock valued at $257,607. 5.20% of the stock is owned by insiders.

Hedge Funds Weigh In On Replimune Group

A number of institutional investors and hedge funds have recently modified their holdings of REPL. Russell Investments Group Ltd. raised its position in shares of Replimune Group by 3,638.9% during the third quarter. Russell Investments Group Ltd. now owns 7,777 shares of the company’s stock worth $33,000 after purchasing an additional 7,569 shares during the period. BNP Paribas Financial Markets raised its stake in shares of Replimune Group by 99.8% in the third quarter. BNP Paribas Financial Markets now owns 13,762 shares of the company’s stock valued at $58,000 after buying an additional 6,873 shares during the period. Raymond James Financial Inc. purchased a new stake in Replimune Group during the second quarter valued at about $69,000. GSA Capital Partners LLP purchased a new position in Replimune Group in the 3rd quarter valued at approximately $81,000. Finally, Griffin Asset Management Inc. bought a new stake in Replimune Group during the 3rd quarter valued at $82,000. 92.53% of the stock is currently owned by institutional investors.

About Replimune Group

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.